Amycretin reduces weight, HbA1c in phase 2 trial
Amycretin reduces weight, HbA1c in phase 2 trial of patients with diabetes Key takeaways: - A novel GLP-1 and amylin receptor agonist reduced HbA1c and weight vs. placebo in patients with type 2 diabetes. - Ph…
Read guide →